Nivolumab Injection

Anter

• Ma mua o ka loaʻa ʻana o ka nivolumab injection,

Hoʻohana ʻia ka pahu kui Nivolumab:

• ʻo ia a i ʻole hui pū ʻia me ipilimumab (Yervoy) e mālama i kekahi ʻano melanoma (kahi ʻano maʻi ʻaʻai ʻili) i pāhola ʻia i nā ʻāpana ʻē aʻe o ke kino a i ʻole hiki ke lawe ʻia e ka ʻoki kino.
• e mālama a pale i ka hoʻi ʻana o kekahi ʻano melanoma ma hope o ke kaha ʻana e hoʻoneʻe iā ia a me nā ʻano a me nā lymph node i hoʻopili ʻia.
• i hui pū ʻia me ipilimumab (Yervoy) e mālama i kekahi ʻano maʻi ʻaʻai o ka maʻi (non-small cell lung cancer; NSCLC) i pāhola ʻia i nā ʻāpana ʻē aʻe o ke kino,
• i ka hui pū me ipilimumab (Yervoy) a me ka platinum chemotherapy e mālama i kekahi ʻano o ka NSCLC i hoʻi a i pāhola paha i nā ʻāpana ʻē aʻe o ke kino.
• ʻo ia wale nō e mālama i kekahi ʻano o ka NSCLC i pālahalaha ʻia i nā ʻāpana ʻē aʻe o ke kino a ua ʻoi aku ka maikaʻi i ka wā a ma hope paha o ka mālama ʻana me nā lāʻau chemotherapy platinum.
• e mālama i kahi ʻano maʻi ʻaʻai ʻē aʻe (ka maʻi ʻaʻai liʻiliʻi liʻiliʻi, SCLC) i pālahalaha ʻia i nā ʻāpana ʻē aʻe o ke kino i ʻino ma hope o ka lapaʻau ʻana ma hope o ka chemotherapy platinum a me ka liʻiliʻi o hoʻokahi lāʻau chemotherapy,
• e mālama i ka carcinoma kōkō ʻoi loa (RCC, kahi ʻano maʻi ʻaʻai e hoʻomaka i nā hunaola o nā puʻupaʻa) i ʻoi aku ka maikaʻi ma hope o ka mālama ʻana me nā lāʻau chemotherapy ʻē aʻe,
• i ka hui pū me ipilimumab (Yervoy) e mālama i ka RCC holomua i ka poʻe i mālama ʻole ʻia me nā lāʻau chemotherapy ʻē aʻe,
• e mālama i ka lymphoma o Hodgkin (ka maʻi ʻo Hodgkin) i nā mākua i ʻoi aku a i ʻole pane ʻole i ka transplant cell autologous (ke kaʻina e lawe ʻia ai kekahi mau hunaola mai ke kino a hoʻi hou i ke kino ma hope o ka chemotherapy a me / a i ʻole ka mālama radiation) a me ka brentuximab vedotin (Adcetris) lapaʻau a i ʻole ma ka liʻiliʻi he ʻekolu mau lapaʻau ʻē aʻe e like me ka transplant cell stem,
• e mālama i kekahi ʻano maʻi poʻo o ke poʻo a me ka ʻāʻī e hoʻi mau nei a i ʻole pālahalaha ʻia i nā ʻāpana ʻē aʻe o ke kino a i ʻole i ʻoi aku ka maikaʻi i ka wā a ma hope paha o ka mālama ʻana me nā lāʻau chemotherapy ʻē aʻe,
• e mālama i ka maʻi ʻaʻai urothelial (ka maʻi ʻaʻai o ka pale o ka ʻai a me nā ʻāpana ʻē aʻe o ka maʻi urinary) i pāhola ʻia i nā ʻāpana ʻē aʻe o ke kino a ua ʻoi aku ka maikaʻi i ka wā a ma hope paha o ka mālama ʻana me nā lāʻau chemotherapy ʻē aʻe,
• ʻo ia a i ʻole hui pū ʻia me ipilimumab e mālama i kekahi ʻano o ka maʻi ʻaʻai kala (kanesa e hoʻomaka i ka ʻōpū nui) i nā mākua a me nā keiki he 12 mau makahiki a ʻoi paha i pāhola aʻe i nā ʻāpana ʻē aʻe o ke kino a ua ʻino hoʻi ma hope o ka lapaʻau ʻana me nā chemotherapy ʻē aʻe. nā lāʻau,
• ʻo ia wale nō a i ʻole hui pū ʻia me ipilimumab e mālama i ka maʻi kanesa hepatocellular (HCC; kahi ʻano maʻi ʻaʻai ate) i ka poʻe i mālama ʻia me ka sorafenib (Nexafar),
• e mālama i ka maʻi ʻaʻai ʻeleʻele esophageal (ka maʻi ʻaʻai o ka paipu e hoʻopili i kou ʻāʻī i kou ʻōpū) i pālahalaha ʻia i nā ʻāpana ʻē aʻe o ke kino, ua ʻoi aku ka ʻino ma hope o ka lapaʻau ʻana me nā lāʻau chemotherapy ʻē aʻe, a i ʻole hiki ʻole ke mālama ʻia me ke kaha
• a i ka hui pū ʻana me ipilimumab e mālama i nā mesothelioma pleural malignant (kahi ʻano o ka maʻi ʻaʻai e hoʻopili i ka pale o ka māmā a me ka umauma o ka umauma) i nā mākua ʻaʻole hiki ke hemo e ke ʻoki.

Aia ʻo Nivolumab i loko o ka papa o nā lāʻau i kapa ʻia he monoclonal antibodies. Hana ia ma ke kōkua ʻana i kāu ʻōnaehana pale e hoʻolohi a kū i ka ulu ʻana o nā hunaola maʻi ʻaʻai.

Hele mai ʻo Nivolumab ma ke ʻano he wai e hoʻokomo ʻia i loko o ke aa i 30 mau minuke e ke kauka a kahu hānai paha i kahi haukapila a i ʻole kahi wahi olakino. Ke hāʻawi wale ʻia ʻo nivolumab e mālama i ka melanoma, ka maʻi ʻaʻai liʻiliʻi liʻiliʻi ʻole (NSCLC), ka Hodgkin lymphoma, ke poʻo poʻo a me ka ʻāʻī, ka maʻi ʻaʻai urothelial, RCC kiʻekiʻe, ka maʻi ʻaʻai kala, ka maʻi ʻaʻai maʻi esophageal squamous, a i ʻole ka maʻi maʻi hepatocellular. i kēlā me kēia 2 a i ʻole 4 mau pule e pili ana i kāu hana no ka mea ke koi aku kāu kauka e loaʻa iā ʻoe ka lāʻau. Ke hāʻawi hoʻokahi ʻia ʻo nivolumab e mālama i ka maʻi ʻaʻai liʻiliʻi liʻiliʻi (SCLC), hāʻawi pinepine ʻia hoʻokahi manawa i kēlā me kēia 2 mau pule no ka mea ke koi aku kāu kauka e loaʻa iā ʻoe ka lāʻau. Ke hāʻawi ʻia ʻo nivolumab me ka ipilimumab e mālama ai i ka melanoma, ka maʻi maʻi hepatocellular, ka maʻi ʻaʻai kala, a i ʻole RCC, hāʻawi pinepine ʻia ia i kēlā me kēia 3 mau pule no 4 mau kiʻina me ka ipilimumab, a laila hoʻokahi wale nō i kēlā me kēia 2 a i ʻole 4 mau pule e pili ana i kāu hana no as ke koi aku kāu kauka e loaʻa iā ʻoe ka lāʻau. Ke hāʻawi ʻia ʻo nivolumab me ka ipilimumab e mālama iā NSCLC, hāʻawi pinepine ʻia hoʻokahi manawa i kēlā me kēia 2 mau pule no ka mea ke koi aku kāu kauka e loaʻa iā ʻoe ka lāʻau. Ke hāʻawi ʻia ʻo nivolumab me ka ipilimumab e mālama i ka mesothelioma pleural malignant, hāʻawi pinepine ʻia i kēlā me kēia 3 mau pule no ka mea ke koi aku kāu kauka e loaʻa iā ʻoe ka lāʻau. Ke hāʻawi ʻia ʻo nivolumab me ka ipilimumab a me ka chemotherapy platinum e mālama ai iā NSCLC, hāʻawi pinepine ʻia hoʻokahi manawa i kēlā me kēia 3 mau pule no ka lōʻihi o ke koi ʻana o kāu kauka e loaʻa iā ʻoe ka lāʻau.

Hiki i ka Nivolumab ke hana i nā hopena koʻikoʻi a hoʻoweliweli paha i ke ola. E nānā pono kahi kauka a kahu hānai paha iā ʻoe ke loaʻa nei ʻoe i ka infusion a ma hope koke iho o ka infusion e hōʻoia ʻaʻole ʻoe i kahi hopena koʻikoʻi i ka lāʻau. E haʻi koke aku i kāu kauka a kahu hānai paha inā ʻike ʻoe i kekahi o nā ʻōuli e hiki ke hana ʻia i ka wā o ka infusion: haʻalulu a haʻalulu, ʻili, ʻehu, pīpī, paʻakikī i ka hanu ʻana, pākī, pehu, a me ka maʻule.

E hoʻolohi paha kāu kauka i kāu infusion, hoʻolohi iā ia, a i ʻole hoʻopau i kāu mālama ʻana me ka inikū nivolumab, a i ʻole mālama iā ʻoe me nā lāʻau hou aʻe e pili ana i kāu pane i ka lāʻau a me nā hopena ʻē aʻe āu e ʻike ai. E kamaʻilio me kāu kauka e pili ana i kou ʻano i kāu mālama ʻana.

E hāʻawi aku kāu kauka a kauka paha iā ʻoe i ka pepa ʻikepili a ka mea hana (Kauka Lapaʻau) ke hoʻomaka ʻoe i ka lāʻau me ka inikua nivolumab. E heluhelu pono i ka ʻike a nīnau i kāu kauka a kauka paha inā he nīnau kāu.

Kau ʻia kēia lāʻau no nā hoʻohana ʻē aʻe; e noi i kāu kauka a kauka paha no ka ʻike hou aku.

Ma mua o ka loaʻa ʻana o ka nivolumab injection,

• e haʻi i kāu kauka a me kāu kauka lāʻau inā he maʻi ʻoe i ka nivolumab, i nā lāʻau ʻē aʻe, a i ʻole kekahi o nā mea hoʻohui i ka inikua nivolumab. E noi i kāu kauka lāʻau a nānā i ke alakaʻi lāʻau no kahi papa inoa o nā mea hoʻohui.
• e haʻi i kāu kauka a me ka mea kauka lāʻau i nā lāʻau lapaʻau, nā wikamina, nā mea hoʻopihapiha, a me nā huahana lāʻau āu e lawe nei a hoʻolālā paha e lawe. Pono paha kāu kauka e hoʻololi i nā kaha o kāu mau lāʻau a nānā pono iā ʻoe no nā hopena ʻaoʻao.
• e haʻi i kāu kauka inā loaʻa iā ʻoe kahi transplant organ. E haʻi pū aku i kāu kauka inā loaʻa a loaʻa paha iā ʻoe kahi maʻi autoimmune (ke ʻano e hoʻouka ai ka ʻōnaehana pale i kahi ʻaoʻao olakino o ke kino) e like me ka maʻi o Crohn (ke ʻano e hoʻouka ai ka ʻōnaehana pale i ka uhi o ka ʻaoʻao digestive e hōʻeha ai i ka ʻeha, diarrhea, weight loss, and fever), ulcerative colitis (ke kumu o ka pehu ʻana a me nā ʻeha ma ka ʻaoʻao o ke kolona [ʻōpū nui] a me ke kīhā), a i ʻole lupus (ke ʻano e hoʻouka aku ai ka ʻōnaehana pale i nā aʻa a me nā ʻola me ka ʻili. nā hono, ke koko, a me nā puʻupaʻa); kekahi ʻano maʻi maʻi a i ʻole nā ​​pilikia hanu; a i ʻole thyroid, kidney a maʻi maʻi ake paha.
• e haʻi i kāu kauka inā hāpai ʻoe a i ʻole hoʻolālā e hāpai. Pono ʻoe e lawe i kahi hōʻike hāpai ma mua o kou loaʻa ʻana i ka nivolumab. ʻAʻole pono ʻoe e hāpai i ka wā e loaʻa ana iā ʻoe ka nivolumab injection. Pono ʻoe e hoʻohana i ka kaohi hānau kūpono e pale ai i ka hāpai ʻana i kāu wā lapaʻau me ka inikū nivolumab a no 5 mau mahina ma hope o kāu hopena hope loa. E kamaʻilio me kāu kauka e pili ana i nā hana kaohi hānau e holo pono nāu. Inā hāpai ʻoe i ka loaʻa ʻana o ka injection nivolumab, kāhea koke i kāu kauka. Hoʻopilikia paha ka piʻo Nivolumab i ka fetus.
• e haʻi i kāu kauka inā e hānai ana ʻoe i ka waiū a i ʻole hoʻolālā e hānai. ʻAʻole pono ʻoe e hānai i ka wā e loaʻa ana i ka nivolumab injection a no 5 mau mahina ma hope o kāu hopena hope loa.

Inā ʻaʻole haʻi kāu kauka iā ʻoe, e hoʻomau i kāu papaʻai maʻamau.

Inā ʻoe e nalo i kahi manawa e loaʻa ai ka injection nivolumab, e kāhea koke i kāu kauka.

Hoʻokumu paha ka injection Nivolumab i nā hopena ʻaoʻao. E haʻi i kāu kauka inā koʻikoʻi kekahi o kēia mau ʻōuli a mai hele aku paha:

• ami, kua, iwi ā, ʻehaʻeha iwi paha
• ʻehaʻeha a nāwaliwali paha
• ʻili maloʻo, māwae, wīwī
• ʻulaʻula, pehu, a ʻeha paha ma nā poho o kou lima a i ʻole nā ​​kapuaʻi o kou mau wāwae
• ʻeha nā waha
• maka maloʻo a waha paha

Hiki i kekahi o nā hopena ʻaoʻao ke koʻikoʻi. Inā ʻoe e ʻike i kekahi o kēia mau ʻōuli a i ʻole i helu ʻia i ka ʻaoʻao HOW, e haʻi koke aku i kāu kauka a i ʻole e kiʻi i ka lāʻau olakino olakino.

• pokole o ka hanu
• ʻūhū hou a i ʻole worsening paha
• kahe ana ke koko
• ʻeha ka umauma
• pāhoehoe
• ʻeha o ka ʻōpū a palupalu paha
• ʻōpala i ʻeleʻele, hoʻoluhi, palu, a i ʻole loaʻa i ke koko
• nāwaliwali a nāwaliwali paha
• ʻano anuanu
• ka hohonu ʻana o ka leo a i ʻole ke kani ʻana
• nā loli i ke kaupaona (loaʻa a pohō paha)
• nā loli i ke ʻano a me ke ʻano (hoʻemi i ka hoʻokau wahine, ka huhū, a me ka hoʻopoina)
• ʻāʻī ʻoʻoleʻa
• ʻeha, puhi, ʻā, a mū ʻole paha i nā lima a me nā wāwae
• ʻeha poʻo, me nā mea ʻano ʻē a hele ʻole paha
• hallucination (ke ʻike nei i nā mea a i ʻole ka lohe ʻana i nā leo i ʻole ola)
• ka hopu ʻana
• huikau
• fiva
• poho lauoho
• ʻili, ʻehu, hives, a palapū paha i kou ʻili
• kōpaʻa
• nausea
• ka luaʻi
• hiamoe
• paupauaho a maʻule paha
• melemele o ka ʻili a mau maka paha, mimi ʻeleʻele ʻeleʻele, kahe ʻana o ke kahe a i ʻole ka palu ma mua o ka maʻamau, ka nele o ka makemake, hoʻemi i ka ikehu, a ʻeha paha ma ka ʻaoʻao ʻākau o ka ʻōpū
• hoʻonui ka make wai
• hoʻemi a hoʻonui i ka urination
• pehu o ka maka, nā lima, nā wāwae, nā wāwae a me nā kuʻekuʻe wāwae
• koko i ka mimi
• nā hoʻololi i ka hihiʻo
• hanu ʻaʻala ʻaʻala

Hoʻokumu paha ka injection Nivolumab i nā hopena ʻē aʻe. Kāhea i kāu kauka inā loaʻa iā ʻoe kekahi pilikia maʻamau i ka loaʻa ʻana o kēia lāʻau.

Inā ʻoe e ʻike i kahi hopena koʻikoʻi, e hoʻouna ʻoe a i ʻole kāu kauka i kahi hōʻike i ka papahana hōʻike ʻino a MedWatch Adverse Event Food (FDA) ma ka pūnaewele (http://www.fda.gov/Safety/MedWatch) a i ʻole kelepona. 1-800-332-1088).

E mālama i nā manawa a pau me kāu kauka a me ka hale hana. E kauoha aku kāu kauka i kekahi mau hoʻokolohua lab e nānā i ka pane o kou kino i ka nivolumab injection. No kekahi mau kūlana, e kauoha kāu kauka i kahi hoʻokolohua hoʻokolohua ma mua o kou hoʻomaka ʻana i kāu lāʻau e ʻike inā hiki ke mālama ʻia i kou kanesa me ka nivolumab.

He mea nui iā ʻoe e mālama i kahi papa inoa i kākau ʻia a me nā lāʻau lapaʻau ʻole (over-the-counter) lāʻau āu e lawe nei, a me nā huahana e like me nā huaora, nā minelala, a i ʻole nā ​​mea hoʻopiliʻai aʻe. Pono ʻoe e lawe i kēia papa inoa me ʻoe i kēlā me kēia manawa ke kipa ʻoe i ke kauka a i ʻole inā ʻae ʻia ʻoe i kahi haukapila. He ʻike nui nō hoʻi ia e lawe pū me ʻoe inā pilikia ʻo ka pilikia.

• Opdivo^®